Matching cardiac rhythm management technology to patient needs: pacing/ablation/implantable cardioverter defibrillators.
Data from 2 decades of clinical electrophysiologic studies have allowed great progress in the evaluation and treatment of patients with sustained ventricular arrhythmias and the appropriate identification of those patients at high risk for subsequent sudden death. The goals of treatment of the patient with ventricular arrhythmias are to suppress symptoms and prevent a fatal event. The steps in providing such therapy include (1) defining the cardiac anatomy; (2) assessing arrhythmia risk through noninvasive or invasive testing; and (3) prescribing treatment based on these results. Patients may be separated into high- and low-risk groups to help identify appropriate treatment. Although low-risk groups may benefit from reassurance or medications such as beta-blockers or verapamil, high-risk groups have been more difficult to treat. Recent randomized trials of implantable cardioverter defibrillators (ICDs) for ventricular arrhythmias suggest that they may provide better protection for high-risk patients than do antiarrhythmic medications.
Cannom
D S
DS
University of California-Los Angeles School of Medicine, Division of Cardiology, Good Samaritan Hospital, Los Angeles, California, USA.
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D002304:Cardiac Pacing, Artificial / Q000379:methods*; D016887:Cardiopulmonary Resuscitation; D017115:Catheter Ablation / Q000379:methods*; D016757:Death, Sudden, Cardiac / Q000209:etiology / Q000517:prevention & control; D017147:Defibrillators, Implantable; D004554:Electric Countershock / Q000295:instrumentation*; D006801:Humans; D012306:Risk; D017180:Tachycardia, Ventricular / Q000150:complications / Q000401:mortality / Q000628:therapy*; D018487:Ventricular Dysfunction, Left / Q000150:complications / Q000401:mortality; D014693:Ventricular Fibrillation / Q000150:complications / Q000401:mortality / Q000628:therapy*
D000889:Anti-Arrhythmia Agents